La realización de cualquier investigación con seres humanos o sus muestras biológicas
requiere una valoración ética previa con el fin de evitar riesgos y problemas a todos los …

Objectives To examine the accessibility and quality of drug company payment data in
Europe. Design Comparative policy review of payment data in countries with different …

Objective To estimate the association between oncologists' receipt of payments from the
pharmaceutical industry and delivery of non-recommended or low value interventions …

Objective To assess the accuracy of self-reported financial conflict-of-interest (COI)
disclosures in the New England Journal of Medicine (NEJM) and the Journal of the …

Evidence-based medicine is the cornerstone of shared-decision making in healthcare today.
The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet …

Introduction Although hospitals are key health service providers, their financial ties to drug
companies are little understood. We examine non-research pharmaceutical industry …

Background: Continuing professional development (CPD) provides support to healthcare
workers to keep up to date with best practices and addresses deficits in their knowledge and …

Background: Creating new therapies often involves drug companies paying healthcare
professionals and institutions for research and development (R&D) activities, including …

The Cleveland Clinic Innovation Management and Conflict of Interest (“IM&COI”) Program
implemented a policy on Conflicts of Interest in Clinical Practice in 2013. The policy requires …

Background The information provided to participants of adaptive platform trials assessing
therapies for COVID-19 inpatients is unknown. We aim to evaluate it by reviewing participant …